drugset / Trial / NCT04185246
A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography
NaSequentialOpen-labelDiagnostic
Summary
NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular (LV) chamber and to improve the delineation of the LV endocardial border. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of NH002.
Timeline
- Start
- 2019-11-04
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NH002 | Diagnostic / imaging agent | 2.5 unknown | Intravenous |
| Subject | NH002 | Diagnostic / imaging agent | 5 unknown | Intravenous |
| Subject | NH002 | Diagnostic / imaging agent | 10 unknown | Intravenous |